QuickView: Clinical catalysts to boost awareness
Bone Therapeutics develops therapies to prevent and treat fractures by addressing underlying problems in bone regeneration. In November, the company’s allogeneic cell therapy product, ALLOB, received Orphan Drug Designation (ODD) from the EMA and the US FDA for the treatment of the genetic bone disorder osteogenesis imperfecta. Over the next two years, we expect frequent clinical development updates from Phase II and Phase III trials to boost awareness and interest in Bone Therapeutics’ cell therapy technology and investment case.Bone Therapeutics is a biotechnology company with an advanced clinical pipeline of cell products for orthopaedic conditions and bone diseases (two Phase II/III and three Phase I/II clinical studies). These areas are characterized by high unmet medical needs due to the lack of efficacious and safe, non-invasive, treatments. Co. has two products in clinical trials, its allogeneic bone cell therapy product, ALLOB®, and its autologous bone cell therapy product, PREOB®. Co. is also conducting preclinical research on next generation products, such as combined cell-matrix products for large bone defects and maxillofacial.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.